We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock

Delisted

SRRA was delisted on the 30th of June, 2022.

44 hedge funds and large institutions have $25.7M invested in Sierra Oncology, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

12% less funds holding

Funds holding: 5044 (-6)

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

82% less capital invested

Capital invested by funds: $140M → $25.7M (-$115M)

Holders
44
Holders Change
-6
Holders Change %
-12%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
14
Increased
11
Reduced
10
Closed
20
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
William Blair & Company
26
William Blair & Company
Illinois
$33K +$79.5K +417 New
WS
27
Wedbush Securities
California
$33K +$80.2K +421 New
Bank of America
28
Bank of America
North Carolina
$32K +$40.8K +214 +116%
Deutsche Bank
29
Deutsche Bank
Germany
$29K -$12.6K -66 -15%
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$26K -$572 -3 -0.9%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$26K
DTL
32
Dynamic Technology Lab
Singapore
$26K +$61.5K +323 New
ARTA
33
A.R.T. Advisors
New York
$24K -$19.1K -100 -25%
RJT
34
Raymond James Trust
Florida
$23K +$55.3K +290 New
Connor, Clark & Lunn Investment Management (CC&L)
35
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$22K +$52.4K +275 New
Comerica Bank
36
Comerica Bank
Texas
$20K -$95.3K -500 -66%
Barclays
37
Barclays
United Kingdom
$16K +$36.2K +190 +3,800%
Citigroup
38
Citigroup
New York
$8K -$762 -4 -4%
UBS Group
39
UBS Group
Switzerland
$8K +$19.8K +104 New
PMFA
40
Plante Moran Financial Advisors
Michigan
$8K +$20.2K +106 New
TRCT
41
Tower Research Capital (TRC)
New York
$4K +$5.53K +29 +193%
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$2K +$6.48K +34 New
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$207
O
45
OrbiMed
New York
-$10.9M -40,579 Closed
RIM
46
RS Investment Management
California
-$6.61M -24,508 Closed
JHIU
47
Janus Henderson Investors US
Colorado
-$5.4M -20,030 Closed
Franklin Resources
48
Franklin Resources
California
-$1.69M -6,253 Closed
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
-$405K -1,504 Closed
CAM
50
Cormorant Asset Management
Massachusetts
-$358K -1,329 Closed

SRRA Hedge Fund Activity: Q2 2016 in Review

44 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2016, worth a combined $25.7M — down 82% from $140M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of SRRA and 14 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 11 added.

The largest buyer was Pictet Asset Management (UK), adding an estimated $2.95M. The largest seller was Fidelity Investments, cutting an estimated $20.1M.

  • 44 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2016, down from 50 in Q1 2016.
  • Funds reported $25.7M of Sierra Oncology, Inc. Common Stock stock for Q2 2016, down 82% quarter-over-quarter.
  • 14 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2016 and 20 closed out, a net change of -6 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $2.95M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q2 2016 was Fidelity Investments, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2016.